Please use this identifier to cite or link to this item:
Title: Effect of genetic variations on ticagrelor plasma levels and clinical outcomes
Authors: Varenhorst, Christoph;Eriksson, Niclas;Johansson, Åsa;Barratt, Bryan J;Hagström, Emil;Åkerblom, Axel;Syvänen, Ann-Christine;Becker, Richard C;James, Stefan K;Katus, Hugo A;Husted, Steen;Steg, Ph Gabriel;Siegbahn, Agneta;Voora, Deepak;Teng, Renli;Storey, Robert F;Wallentin, Lars
Year: 1-Aug-2015
Abstract: Ticagrelor, a direct-acting P2Y12-receptor antagonist, is rapidly absorbed and partly metabolized to the major metabolite AR-C124910XX (ARC). To identify single-nucleotide polymorphisms (SNPs) associated with pharmacokinetics of ticagrelor and clinical outcomes, we performed a genome-wide association study (GWAS) in patients treated with ticagrelor in the PLATO trial.
ISSN: 10.1093/eurheartj/ehv116
Appears in Collections:European Heart Journal 2015

Files in This Item:
File Description SizeFormat 
1901.full.pdf892.57 kBAdobe PDFThumbnail
Download    Request a copy

Items in HannanDL are protected by copyright, with all rights reserved, unless otherwise indicated.